I respectfully disagree here. IF amrn has stellar results the drug will sell itself. The reduce it study is one in which physicians will be made aware of. This would be a blockbuster drug and every internist family practice physician cardiologist and others will probably get a news alert just based on the buzz. New trials like this that show significant patient health benefit get sent via email to us (provided they are a physician that gets evidenced based articles) Plus with no major side effects it will quickly replace the current market TG lowering drugs and likely be a candidate to be in the cardiovascular national guidelines as an adjuvant therapy. What then Happends is everyone will be prescribing and taking vascepa even if they are not the intended patient population. Example , many people take aspirin and you ask then why and they have no indication to be on aspirin but they take it bc they know it helps people who had a heart attack so they figure why not take it before I have a heart attack (not been shown to help).
Anyways the other point is , if this is a success (which i believe it to be as safe a bet as any in my opinion) , the stock price jump will be in one day. Thus you will not need to worry about the future sales etc bc in one day it will go from let's say 5 bucks pre results to 10-20 after.
I've been in amrn for all its trials. Marine took it 3 to 6 (one day ) Anchor took it from 6 to 17 or 18 (one day ) forgot exactly where I sold it. This would be much more powerful than those.